The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto, Young‐Jun Park, Martina Beltramello et al. · Nature · 2020 · 2.1K citations · Full text

Vaccine Target, Immunology, Antibody Engineering +2

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

Oliver C. Grant, David W. Montgomery, Keigo Ito et al. · Scientific Reports · 2020 · 407 citations · Full text

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

Yasunori Watanabe, Zachary T. Berndsen, Jayna Raghwani et al. · Nature Communications · 2020 · 393 citations · Full text

High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

For Yue Tso, Salum J. Lidenge, Phoebe B. Peña et al. · International Journal of Infectious Diseases · 2020 · 257 citations · Full text

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses

Jason T. Ladner, Sierra N. Henson, Annalee S. Boyle et al. · Cell Reports Medicine · 2021 · 217 citations · Full text